Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Head and Neck Cancer

Interventions

DRUG

Amifostine

500 mg in two divided doses subcutaneously given 30-60 minutes prior to IMRT.

PROCEDURE

Intensity- Modulated Radiation Therapy

2.0 to 2.2 Gy delivered in 30 fractions

Trial Locations (1)

U.T. M.D. Anderson Cancer Center, Houston